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1. Introduction 
Cytokines are messengers that coordinate the development and function of leukocytes and 
therefore are indispensable for the initiation, maintenance and termination of all types of 
immune responses. A tight control of cytokine functions is crucial for both, the control of 
infections and the prevention of infection-associated immunopathology. Different 
intracellular mechanisms of cytokine signal inhibition are involved in the regulation of 
innate and adaptive immune responses. Among these, the family of suppressor of cytokine 
signalling (SOCS) proteins identified more than a decade ago (Endo et al. 1997; Naka et al. 
1997; Starr et al. 1997) are non-redundant negative feedback inhibitors of both pro-
inflammatory but also of anti-inflammatory cytokine responses (Kubo et al. 2003; Yoshimura 
et al. 2007).  
Type I and type II cytokine receptors do not possess a cytoplasmic kinase activity and 
therefore are dependent on associated Janus kinases (JAKs). JAKs conduct the signal of 
many cytokines including many interleukins (IL), all interferons (IFN) and hemopoietins. 
Activated JAKs cross-phosphorylate themselves and phosphorylate the associated cytokine 
receptor creating binding sites for proteins that contain phosphotyrosine binding SH2 
domains. The SH2 domain of signal transducers and activators of transcription (STATs) then 
binds to the phosphorylated receptors. Recruited STATs get phosphorylated by the adjacent 
JAKs, and act as binding sites for the SH2 domain of another STATs, which also will be 
phosphorylated. The STAT dimer translocates into the nucleus where it acts as a 
transcription factor activating the transcription of specific genes. The diversity of STAT-
mediated intracellular pathways is due to the presence of 7 STATs, activated by different 
receptors. Moreover, activated STAT dimers act as homo- or heterodimers, which increases 
the diversity of target promoters and thereby of gene patterns that can be activated. 
The JAK-STAT pathway can be negatively regulated at different stages: protein tyrosine 
phosphatases remove phosphates from cytokine receptors and activated STATs, whereas 
PIAS (protein inhibitors of activated STATs) act in the nucleus (Leonard & O'Shea 1998; 
Krebs & Hilton 2001; Hebenstreit et al. 2005; Shuai 2006).  In this chapter we will focus on the 
role of another inhibitor of the JAK-STAT pathway, the SOCS proteins. The importance of 
these proteins is evidenced by the fact that mice deficient for some of the SOCS proteins 
demonstrated a non-redundant role of SOCS proteins in regulating the immune system 
(Alexander 2002). 
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SOCS proteins play a role in balancing immune functions at different levels, including the 
differentiation of immune cell populations and their activation by environmental stimuli. 
Both deletion and over-expression of SOCS proteins in animal models provided insights 
into their importance of regulating the responsiveness to cytokines. Accumulated today’s 
knowledge on the immunobiology of SOCS proteins convert them into new potential targets 
for treatment of inflammatory diseases but might also help to improve infection control. 
2. SOCS at the molecular level 
The family of SOCS proteins consists of 8 members (cytokine inducible SH2 protein, CIS, 
SOCS1-7), which share a central modulator organization with a SH2 domain, a C-terminal 
SOCS box and an amino-terminal domain of variable length (fig. 1).  The SOCS-box was 
shown to interact with elongin A and B, cullin 5 and ring box. This complex acts as an E3 
ubiquitin ligase, initiating ubiquitination in other words the covalent binding of ubiquitin to 
target proteins, which is followed by the proteosomal degradation of bound signalling 
complexes as JAKs and cytokine receptors (Verdier et al. 1998; Kamura et al. 2004; Piessevaux et 
al. 2008). The SH2 domain of SOCS proteins determines the specificity of the SOCS and CIS 
proteins for the respective cytokine receptors (Endo et al. 1997; Nicholson et al. 2000).  
So far, SOCS1 and SOCS3 are the most studied SOCS proteins. They both contain a N-
terminal kinase inhibitory region (KIR) that is absent in other SOCS proteins (fig. 1).  The 
KIRs of SOCS1 and SOCS3 can directly inhibit JAK tyrosine kinase activity, acting as 
pseudo-substrates, and by that can block the interaction of JAKs with their substrate STAT 
molecules. JAK inhibition by SOCS1 and 3 takes place even in the absence of the SOCS box 
(Yasukawa et al. 1999; Zhang et al. 2001). SOCS1 can bind to the catalytic domain of JAK2 
and to Tyk2 a molecule of the JAK family that mediates IFN- signalling. SOCS1 has also 
been shown to bind directly to type I IFN receptors (IFNar1) (Fenner et al. 2006) and to the 
IFN- receptor inhibiting efficiently STAT1-mediated signalling (Kubo et al. 2003; Qing et al. 
2005; Fenner et al. 2006). Furthermore, SOCS1 can bind to the insulin receptor (Mooney et al. 
2001; Rui et al. 2002) and to the glucocorticoid receptor via its SH2 domain (Haffner et al. 
2008). Besides JAK2, SOCS3 binds to a variety of receptors as the common IL-6 family co-
receptor gp130 at the phosphorylated tyrosine 757, erythropoietin receptor, granulocyte 
colony stimulating factor (GCSF) receptor, growth hormone receptor (Hansen et al. 1999;  
 
 
Fig. 1. Schematic structure of SOCS1 and SOCS3 proteins shown in upper panel, SOCS1 and 
SOCS3 as negative regulators of JAK/STAT signalling in lower panel. SOCS1 preferably 
binds directly to the JAK activation loop while the SH2 domain of SOCS3 binds to the 
cytokine receptor. 
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Nicholson et al. 2000; Sasaki et al. 2000; Hortner et al. 2002a; Hortner et al. 2002b) and  
cytokine receptors IL2R and IL-12R1(Cohney et al. 1999; Yamamoto et al. 2003). Possible 
interactions of SOCS1 and SOCS3 with Toll-like Receptor (TLR) signalling have been 
described and will be discussed later. 
3. SOCS1  
SOCS1 is expressed constitutively in the thymus, spleen, lung and testes of mice. SOCS1 
mRNA expression can be rapidly induced by many cytokines, especially IFNs, and serves as 
a classical feed back loop inhibiting its inducing pathway (Naka et al. 1997; Starr et al. 1997). 
Importantly, SOCS1 mRNA expression increases even in response to microbial molecules 
such as LPS, Pam3Cys and CpG oligonucleotides that signal via TLR (Dalpke et al. 2001; 
Alexander 2002; Fujimoto & Naka 2003; Dennis et al. 2006).  Furthermore, hormones like 
insulin (Emanuelli et al. 2000), cardiotrophin (Hamanaka et al. 2001) or glucocorticoids 
(Bhattacharyya et al. 2011) have been shown to stimulate SOCS1 expression.  
SOCS1-/- animals die within 3 weeks after birth due to fatty degeneration and necrosis of the 
liver (Naka et al. 1998; Starr et al. 1998). These mice show retarded growth, lymphopenia and 
multi-organ haematopoietic infiltrates. At least in part, the spontaneous inflammatory 
disease is thought to be due to IFN- hyper-responsiveness of SOCS1-deficient tissue, 
because SOCS1-/-IFN--/- as well as SOCS1-/-STAT1-/- mice survive healthy until adulthood 
(Alexander et al. 1999; Marine et al. 1999b). The importance of IFN- was further apparent in 
mice heterozygous for IFN- and lacking SOCS1 that survived until 5 month of age before 
succumbing with myocardis and polymyositis (Metcalf et al. 2000). SOCS1 mice, treated 
with neutralizing antibodies from birth, died of the same phenotype reaching adulthood 
(Bullen et al. 2001). A similar expected protection from lethality was observed in SOCS1-/- 
crossed with IFN-R-/- and STAT1-/- mice. Furthermore, RAG2-/-SOCS1-/- are healthy to at 
least 3 month of age, implicating that IFN- secreted by T and/ or NKT cells might be 
responsible for the tremendous inflammation observed (Marine et al. 1999b). In fact, 
depletion of NKT cell by antibody-treatment significantly increased the survival of mice. 
Surprisingly, mice with a conditional knock down for SOCS1 in T and NKT cells did not 
display any of the SOCS1-/- pathologies, indicating that a deletion of SOCS1 in T and NKT 
cells is not sufficient for the hyper-inflammation but that this was due an uncontrolled 
response of myeloid cells together with an excessive neonatal IFN- release (Chong et al. 
2003). The fact that myeloid cells are involved was demonstrated by the lethality of chimeric 
mice, which received SOCS1-/- bone marrow after irradiation (Metcalf et al. 2003). On the 
other hand, T cells were also required for SOCS1-mediated lethality since SOCS1-/- mice 
with a SOCS1 transgene expressed only by T cells survived. Interestingly, the survival of 
SOCS1-/- mice also increased when back-crossed to IFNar1-/- mice (lacking one of the IFN-
 R subunits) indicating that even type I IFNs in part contribute to the lethal inflammation 
of SOCS1 deficient animals. Altogether, SOCS1 lethality is mainly due to both an 
exacerbated secretion of IFN- by T and NKT cells during the neonatal period and to a 
hyper-response of myeloid cells to IFN-, but IFN--independent immune responses such as 
type I IFN and others discussed below are also likely to contribute to it.  
The use of conditional knock down mice, as well as in vitro experiments with different 
cell populations allowed a more precise definition of the role of SOCS1 in different cell 
lineages. A combination of SOCS1 conditional knock downs in hematopoetic cells using 
the cre-lox technology confirmed that SOCS1 deficiency in both T cells and macrophages 
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is critical to result in lethal inflammation (Chong et al. 2005). SOCS1fl/- LysM-cre mice 
deficient for SOCS1 in myeloid cells showed signs of morbidity starting from 50 days of 
age with splenomegaly as the most prominent feature. Moribund SOCS1lox/- LysM-cre 
mice showed aberrantly activated T cells and elevated serum levels of IFN-, TNF-α and 
IL-12 p40. SOCS1fl/fl Lck-cre mice, deleted for SOCS1 in T- and NKT-cell compartment did 
not develop lethal multi-organ inflammation but developed multiple lymphoid 
abnormalities, including enhanced differentiation of thymocytes toward CD8 T cells and 
very high percentages of peripheral CD8 T cells with a memory phenotype (Chong et al. 
2005). 
SOCS1-/- mice could also be partially protected from neonatal lethality when crossed with 
STAT1-/-, STAT4-/- or STAT6-/- mice but nevertheless showed a chronic inflammation with 
aberrant T cell activation (Metcalf et al. 2000; Naka et al. 2001; Eyles et al. 2002). STAT6 and 
STAT4 are two STAT family members that specifically mediate signals that emanate from 
the IL-4/ IL-13 and IL-12 receptors, respectively (Wurster et al. 2000). IL-4/ IL-13 and IL-12 
are cytokines that are important regulators of the proliferation, differentiation and 
functional capacity of lymphocytes. Although the impact of genetic deletion of STAT4 and 
STAT6 genes in the survival of SOCS1 deficient animals is lower than that of STAT1, this 
demonstrates that SOCS1 also regulates IL-4 and IL-12 signalling. Uncontrolled responses to 
IL-12, an inflammatory cytokine, could contribute to increased IFN- secretion by T cells 
production and, as indicated above, to the development of inflammatory disease in SOCS1-/- 
mice (Eyles et al. 2002). IL-4, like IFN-, induces de novo expression of SOCS-1 in primary 
macrophages. Induction of SOCS1 gene expression by IL-4 is STAT6-dependent and SOCS1 
feedback inhibits expression of STAT6-responsive genes. Upon binding to their ligand the 
IL-4 and IL-12 receptors induce tyrosine phosphorylation of the JAK2 protein kinase 
(Wurster et al. 2000). In relation, SOCS1 deletion in T cells resulted in an elevated production 
of both IFN- and IL-4, which might indicate an enhanced function of Th2 populations in 
addition to Th1 cells. Overexpression of SOCS1 in Th2 cells has been shown to repress 
STAT6 activation and inhibit IL-4-induced proliferation, while depletion of SOCS1 by an 
anti-sense SOCS1 enhanced cell proliferation and induced activation of STAT6 in Th2 cells 
(Yu et al. 2004). On the other hand, the role of SOCS1 in a Th2 skewed immune responses 
has been suggested (Lee et al. 2009), in relation to the fact that SOCS1 expression is 5-fold 
higher in Th1 than in Th2 cells (Egwuagu et al. 2002).  
Dendritic cells (DCs) play a critical role in initiating and regulating adaptive immune 
responses. Silencing of SOCS1 in DCs broke self-tolerance to tumor antigens and increased 
the magnitude of antigen-presentation (Shen et al. 2004; Evel-Kabler et al. 2006). Moreover, 
the increased responses of SOCS1-/- T and NK cells to IL-12 (Eyles et al. 2002), and the IFN--
mediated inflammatory disease in mice deficient for SOCS1 in regulatory T (Treg) cells (Lu 
et al. 2009; Lu et al. 2010) showed a SOCS1-mediated control of Treg cell function, but also 
highlights the relevance of SOCS1 as target molecule in these diseases. In Treg cells specific 
microRNA regulated SOCS1 expression.  
SOCS1 has also been shown to inhibit B cell proliferation in vitro and autoantibody 
production in vivo, through suppression of BAFF/BLyS a B cell growth and 
differentiation factor, that has been implicated in systemic autoimmune diseases (Hanada 
et al. 2003). 
Taken together, several findings indicate that SOCS1 is involved in the regulation of Th1 
responses by modulating the responses of different immune cells, such as macrophages, 
DCs, Th1 and Treg cells. 
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3.1 Role of SOCS1 in infectious diseases and inflammation 
SOCS1 deficient mice are hypersensitive to LPS-induced endotoxic shock, associated with 
increased levels of IL-12 and TNF- (Kinjyo et al. 2002). Surprisingly, even though IFN-R-/- 
mice are very resistant to endotoxic shock (Car et al. 1994), additional knock-out of IFN- or 
STAT1 did not rescue SOCS1-/- mice from lethal LPS injection, demonstrating that SOCS1 
attenuates IFN-independent mechanisms that mediate septic lethal shock (Car et al. 1994; 
Kinjyo et al. 2002; Nakagawa et al. 2002). Furthermore, elevated sensitivity to endotoxin 
shock was observed in SOCS1fl/fl LysM-cre mice lacking SOCS1 in macrophages and 
neutrophils (Hashimoto et al. 2009b). Another contributing factor to the elevated sensitivity 
might be that SOCS1 mediates the protective effect of cardiotrophin-1 in sepsis-induced 
cardiomyocyte depression (Tanimoto et al. 2005). 
These findings suggest an interaction of SOCS1 with components of TLR signalling 
underlying the role of SOCS1 in protection against septic shock. In fact, binding of SOCS1 to 
IRAK1 and the p65 subunit of NFB has been shown to destabilize and limit NFB 
activation (Kinjyo et al. 2002; Nakagawa et al. 2002; Ryo et al. 2003; Maine et al. 2007). Others 
demonstrated that SOCS1 might also bind to apoptosis signal-regulating kinase 1 (ASK1) 
and regulate mitogen-activated protein kinases JNK and p38 (He et al. 2006). Furthermore, 
SOCS1 was shown to mediate the degradation of the adaptor protein Mal, involved in TLR2 
and TLR4 signalling (Mansell et al. 2006). However, results from other investigators could 
not confirm a direct effect of SOCS1 on TLR signalling (Baetz et al. 2004; Gingras et al. 2004) . 
SOCS1 over-expression did not affect TLR signalling, instead the inhibition of IFN--
mediated STAT1 activation by SOCS1 has been suggested to account for the observed 
sensitivity to LPS in IFN--/-/SOCS1-/- mice (Baetz et al. 2004; Gingras et al. 2004). Thus, 
further work is required to clarify whether SOCS1 is directly involved in the regulation of 
TLR signalling.  
A wide range of pathogens including parasites, bacteria and viruses are potent 
stimulators of SOCS1 expression in the host. Despite obvious differences in the 
immunobiology and in the type of protective or deleterious immune responses elicited, 
for most intracellular infections studied, SOCS1 expression is apparently facilitating 
pathogen replication. But by hampering inflammatory reactions SOCS1 may also improve 
the pathological outcome of infections and thereby reduce morbidity. In this respect, 
manipulation of the immune system by SOCS1 conveys an adaptive advantage to 
pathogens. Microbes replicating in macrophages can be thought of hijacking the host 
SOCS system as an immune evasion mechanism.  
To unravel the role of SOCS1 different infection models knock out and conditional knock 
down mouse strains have been applied. Other tools, such as lentiviruses encoding SOCS1 
siRNA and treatment with small molecules inhibiting or mimicking SOCS1 action have also 
been used. Altogether, targeting SOCS1 may serve as a tool to improve the control of 
different infections and their pathological outcomes. 
3.1.1 Viral infections 
Several viruses including Herpes Simplex Virus (HSV)(Frey et al. 2009), human respiratory 
syncytial virus (RSV) (Hashimoto et al. 2009a), hepatitis C (HCV)(Yao et al. 2011), Ebola 
(Okumura et al. 2010) and human-immunodeficiency (HIV)(Yadav et al. 2009) virus were 
found to up regulate SOCS1 (Yang et al. 2008; Frey et al. 2009; Hashimoto et al. 2009a; 
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Hashimoto et al. 2009b; Okumura et al. 2010; Yao et al. 2011). Since SOCS1 is interfering with 
the type I IFN signalling, a role for SOCS1 in incrementing susceptibility to viral infection 
could be expected.  
SOCS1-/-/IFN--/- mice outlived Semliki Forest virus (SFV)-infected control mice 
substantially (Alexander et al. 1999). Even though serum levels of IFN- were lower in 
infected SOCS1-/- mice than in controls, an increased sensitivity to IFN- was associated to 
resistance. The IFN-ar1 chain of the IFN- receptor was shown to interact with SOCS1 and 
therefore inhibited efficient host responses (Fenner et al. 2006).  
In another model, human T cell lymphotropic virus (HTLV) replication in peripheral blood 
mononuclear cells correlated with induction of SOCS1 and inhibition of IFN- and IFN-
stimulated gene expression (Oliere et al. 2010). These authors also showed that HTLV 
infection-induced SOCS1 mediated proteosomal degradation of IRF3, the blockade of IFN-
gene expression and enhanced viral load. Of importance, SOCS1 did not only inhibit type I 
IFN-mediated viral defences but was found to impair efficient IFN- stimulated anti-
tumoral defences in mice (Zitzmann et al. 2007). 
In vivo, injection of dnSOCS1 construct into the hearts of coxsackievirus-infected mice 
attenuated both virus replication and cardiomyocyte damage, protecting the heart from 
viral infection, suggesting that SOCS1 is a relevant therapeutic target  (Yasukawa et al. 
2003b).  
Recently, specific microRNAs were found to regulate IFN- responses. Infection with 
vesicular stromatitis virus (VSV), was shown to stimulate miR-155 expression that, by 
inhibition of SOCS1, positively regulated host antiviral innate immune response by 
promoting IFN- responses (Wang et al. 2010). Thus, while SOCS1 is up-regulated during 
inflammatory IFN-mediated responses, miRNA might be a new mechanism by which the 
host can fine-tune its antiviral state.  
Besides type I IFNs, responses to IFN- can be an essential component of control of some 
viral infections. The HSV-infection in keratinocytes, stimulated SOCS1 expression and made 
them refractory to IFN-, whereas HSV infected fibroblasts did not increase SOCS1 levels 
and developed an antiviral state after IFN- stimulation (Frey et al. 2009). Treatment of cells 
with a SOCS1 antagonist peptide as well as silencing SOCS1 with siRNA protected 
keratinocytes from HSV-1 infection and restored responsiveness to IFN-  
In contrast to suppression of IFN-mediated protective responses by SOCS1, in other virus 
infections unrestrained immune responses can cause damaging immunopathology. In 
these cases impairment of cytokine responses with SOCS1 may prevent inflammatory 
damage. Thus, in a vaccinia virus infection model, the administration of a small tyrosine 
inhibitor peptide that binds to JAK2 and inhibits STAT1 phosphorylation as well as a 
peptide mimicking the SOCS1 KIR region protected mice against lethal virus infection 
(Ahmed et al. 2009).  
Clinical studies showed T cell exhaustion in chronically HCV-infected individuals. 
Interestingly, the expression of programmed death receptor 1 (PD1) and SOCS1 was 
increased in T cells and macrophages (Frazier et al. 2010; Zhang et al. 2011). In both cell 
types, blocking of PD1 signalling reduced SOCS1 expression and led to improved T cell 
proliferation and IL-12 secretion by macrophages respectively.  
Studies on HIV progressor patients showed that SOCS1 expression was elevated in CD4 T 
cells displaying reduced IRF1 expression after IFN- stimulation in comparison to healthy 
controls (Yadav et al. 2009).  Furthermore, SOCS1 was found to bind to HIV gag protein 
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improving production and stability of HIV-1 particles (Ryo et al. 2008). In a HIV 
vaccination model in mice, silencing of SOCS1 in DC using siRNA increased the secretion 
of IL-12 and other pro-inflammatory cytokines resulting in enhanced memory humoral 
and cellular immune responses (Song et al. 2006). Recently, it was shown that treatment of 
DCs from HIV patients with SOCS1 siRNA augmented the frequency of polyfunctional 
cytotoxic T cells (T cells secreting IL-2, TNF- and IFN-are associated with 
protection)(Subramanya et al. 2010), suggesting that silencing SOCS1 in DCs may 
contribute to improved HIV-vaccination.  
Taken together, SOCS1 induction is a successful tool of various viruses to diminish antiviral 
IFN responses, leading in many of the infections to impaired control of infection. 
3.1.2 Bacterial infections 
Studies on the role of SOCS1 have been focussed on intracellular bacterial infections in 
which IFN- usually plays a major protective role. Research from our laboratory showed 
that Chlamydia pneumoniae infection of macrophages induced SOCS1 expression in a STAT-1 
and IFN-dependent manner (Yang et al. 2008). Infected SOCS1-/- macrophages displayed 
lower bacterial titers and higher levels of IFN-regulated genes as iNOS (inducible nitric 
oxide synthase) and IDO (indoleamine dioxygenase), that participate in the control of 
intracellular bacteria. RAG1-/-/SOCS1-/- mice showed 10-fold lower bacteria numbers in 
lungs than controls 6 days after infection. However, RAG1-/-/SOCS1-/- mice died within 
seven days after infection with C. pneumoniae showing a severe pulmonary inflammation, 
whereas RAG1-/- mice survived for more than 60 days. Thus, SOCS1 has a crucial role in 
preventing lethal inflammation in C. pneumoniae infection. 
Tuberculosis is another disease in which IFN- plays a critical role in containing bacterial 
levels and in the maintenance of the latent asymptomatic disease in infected individuals. 
Infection with different mycobacterial species such as Mycobacterium bovis (Imai et al. 
2003), M. avium (Vazquez et al. 2006) and M. tuberculosis have been shown to stimulate 
SOCS1 in macrophages (Imai et al. 2003; Vazquez et al. 2006; Srivastava et al. 2009; Carow 
et al. 2011). Different innate immune receptors including TLR, NLR and DC-SIGN were 
found to mediate SOCS1 stimulation in mycobacterial infected myeloid cells (Srivastava 
et al. 2009).  
Experiments from our laboratory and others, showed improved M. tuberculosis control in 
SOCS1 deficient macrophages and DCs (Srivastava et al. 2009; Carow et al. 2011). SOCS1-/- 
infected macrophages expressed higher levels of IFN--responsive genes but also higher 
levels of IFN- itself than infected control cells. In agreement, SOCS1-/- macrophages 
secreted higher amounts of IFN- in response to IL-12, and although levels of IL-12 were not 
altered, SOCS1-/- macrophages displayed increased IL-12R1 expression (Fig. 2). Of 
importance, the improved control of M. tuberculosis or M. bovis BCG by SOCS1-/- was lost in 
IFN--/-/SOCS1-/- macrophages, indicating that IFN- secretion mediates the improved 
mycobacterial control by SOCS1-/- macrophages. Moreover, despite SOCS1 expression, M. 
tuberculosis-infected macrophages were unimpaired in their response to IFN-. Altogether, 
as depicted in fig. 2, this suggests that SOCS1 regulates the secretion of rather than the 
response to IFN- via controlling responses to IL-12 and that this causes mycobacterial 
resistance of macrophages. As stated above, SOCS1 regulates STAT4 activation in response 
to IL-12, which probably accounts for this mechanism (Eyles et al. 2002) (Fig. 2). 
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Fig. 2. SOCS1 in M. tuberculosis-infected macrophages 
Macrophage responses and control of M. tuberculosis infection in absence (left panel) or 
presence (right panel) of SOCS1 regulating IFN- mediated genes. 
RAG1-/-SOCS1-/- as well as SOCS1fl/fl LysM-cre mice displayed lower bacterial loads in the 
lungs early after aerosol infection with M. tuberculosis, indicating that SOCS1 expression by 
macrophages facilitates M. tuberculosis infection. However, RAG1-/-/SOCS1-/- and IFN--/-
/SOCS1-/- mice showed a dramatic pulmonary inflammation from 3 weeks after M. 
tuberculosis infection without reduced bacteria numbers in different organs. This 
inflammatory response was caused by SOCS1-deficiency in non-macrophage cells, since it 
was not observed in M. tuberculosis-infected SOCS1fl/fl LysM-cre mice. Overall, M. 
tuberculosis infection induces SOCS1 that by diminishing IL-12 responses impairs IFN- 
secretion by macrophages. This results in lower levels of IFN--regulated genes and in 
increased pulmonary bacterial levels at early time points. Later during infection, SOCS1 in 
non-macrophages cells protects mice from severe inflammation. At these later time points, 
macrophages containing bacteria are able to respond to IFN- and reduce bacterial levels, 
despite SOCS1 expression. Thus, SOCS1 does not mediate resistance to infection at late time 
points (fig. 3).  
A role of SOCS1 in T cells during M. tuberculosis has been envisaged (Srivastava et al. 2011). 
However, SOCS1fl/fl Lck-cre mice deficient for SOCS1 in T cells showed no reduction in M. 
tuberculosis numbers in the lung (unpublished observation). 
We have also analysed the expression of SOCS1 in tuberculosis patients. We found higher 
SOCS1 mRNA levels in blood samples from pulmonary tuberculosis patients than in 
endemic controls (Srivastava et al. 2009; Masood et al. submitted ). Furthermore, SOCS1 
transcripts were raised in T cells of patients with far advanced as compared with those 
showing a moderately advanced disease (Masood et al. submitted ). This confirmed studies 
describing an over-representation of SOCS1 (as well as other interferon-induced genes) in 
active tuberculosis patients compared to latent patients (Berry et al. 2010). 
In summary, SOCS1 possesses two roles during infection: on the one hand it suppresses 
protective immune responses but on the other hand also prevents the development of 
detrimental inflammation. Therefore, it clearly depends on the stage of infection, but also on 
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the type of the infection and the genetics of the host whether SOCS1 improves or worsens 
the outcome of infection.  
 
Fig. 3. Role of SOCS1 during different stages of M. tuberculosis infection  
3.1.3 Parasite infections 
The role of SOCS1 was also studied in a limited number of infections with parasites. SOCS1-
/- mice were resistant to development of cerebral malaria after infection with Plasmodium 
berghei. This is surprising since IFN- mediates cerebral malaria in this model (Bullen et al. 
2003b). However, the underlying mechanisms were not revealed.  
SOCS1-/- macrophages were capable of killing Leishmania major at a 100-fold lower IFN- 
concentration than WT macrophages (Alexander et al. 1999). However, SOCS1+/- L. major-
infected mice showed a worsened infection immunopathology, with larger dermal lesions 
but without reduction of parasites (Bullen et al. 2003a).  
Another parasite, Toxoplasma gondii induced SOCS1 expression in macrophages. SOCS1 
over-expressing macrophages were unable to control parasite growth in response to IFN- 
whereas SOCS1-/- macrophages were restored in their ability to induce IFN- responsive 
genes after T. gondii infection (Zimmermann et al. 2006).  
Moreover, recent data show that implantation of the parasite Brugia malayi, a causative agent 
of lymphatic filariasis, generated Th2 responses associated with development of M2 
macrophages in mice. Expression of SOCS1 not only controlled the secretion of pro-
inflammatory cytokines in M1 macrophages but was involved in maintaining M2 
differentiation (Whyte et al. 2011). In line, patients with filariasis showed increased Th2 and 
impaired Th1 antigen-specific responses, which was associated with increased T cell 
expression by SOCS1 (Babu et al. 2005). Altogether, the function of SOCS1 during infections 
with parasites resembles that in bacterial infections, balancing anti-pathogen responses and 
the severity of inflammation.  
4. SOCS3 
SOCS3 is an important endogenous inhibitor of STAT3-mediated cytokine signalling. SOCS3 
has been shown to be induced by different hormones including ciliary neutrophilic factor, 
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leptin, prolactin and growth hormones (Adams et al. 1998; Bjorbaek et al. 1998; Bjorbaek et al. 
1999; Pezet et al. 1999) and cytokines like leukemia inhibitory factor, IL-11, IL-10, IL-2, IL-27 
and IL-6 (Starr et al. 1997; Auernhammer & Melmed 1999; Bousquet et al. 1999; Cassatella et 
al. 1999; Cohney et al. 1999) but also by microbial molecular patterns as LPS or CpG (Stoiber 
et al. 1999; Dalpke et al. 2001). 
Among these, the role SOCS3 in regulation of IL-6 responses has been studied in detail. 
IL-6 is a pro-inflammatory cytokine that has been found to play a role in many 
inflammatory diseases, while IL-10 is a potent anti-inflammatory cytokine, which 
suppresses gene activation through TLR signalling pathways, but can also inhibit Th1 
responses at different levels. While it is known that STAT3 is essential for the biological 
actions of both IL-6 and IL-10, it was unclear for many years how these two cytokines 
could have exactly opposing functions.  
Interestingly, an inhibitory role for SOCS3 could only be shown for cytokines binding to the 
IL-6 receptor whereas the signalling of IL-10 that also stimulates STAT3-activation was 
unaffected by SOCS3 (Song & Shuai 1998; Lang et al. 2003; Yasukawa et al. 2003a; Kimura et 
al. 2004; Shuai 2006). This is explained by the ability of SOCS3 to bind to the IL-6 receptor 
subunit gp130 (Tyr 759) but not to the IL-10 receptor (Nicholson et al. 2000; Lehmann et al. 
2003; Yasukawa et al. 2003a). STAT3 activation in response to IL-6 is prolonged in absence of 
SOCS3. It has been proposed that the sustained activation of STAT3 is essential for the anti-
inflammatory effect, while transient activation of STAT3 promotes inflammation (Yasukawa 
et al. 2003a). 
Gp130 is a promiscuous cytokine receptor subunit that mediates signalling by IL-6 and other 
cytokines such as IL-11, IL-27, leukemia inhibitory factor (LIF) and cardiotrophin-1 (Taga & 
Kishimoto 1997). Gp130 is present on hematopoietic and nonhematopoietic cells, and its 
expression can vary depending on the cell's activation status (Andersson et al. 1978).  Gp130 
itself does not bind to cytokines but acts as a co-receptor. When the cytokine (for example 
IL-6) binds to the IL-6Ra, it triggers a heterodimeric association with gp130 to form a 
signalling complex (Silver & Hunter 2010).  SOCS3 also modulates signalling of gp-130-
dependent cytokines. Moreover, the mutation of SOCS3 binding site on the gp130 receptor 
increased STAT3 activation in response to IL-6 and stimulated IL-10-like anti-inflammatory 
responses (Ohtani et al. 2000; Croker et al. 2003; Lang et al. 2003; Yasukawa et al. 2003a). Such 
anti-inflammatory responses are abolished when the gp130 Y759 mutated mice possessed a 
monoallelic deletion of STAT3 (McLoughlin et al. 2005; Yoshimura et al. 2007). As already 
mentioned above, SOCS3 inhibits also signalling via non gp130 containing cytokine and 
hormone receptors such as GCSF, leptin, IL-12 and even IFNs (Song & Shuai 1998; Bousquet 
et al. 1999; Bjorbak et al. 2000; Shen et al. 2000; Hortner et al. 2002b).  
SOCS3 knock out mice die during embryonic life due to placental defects (Marine et al. 
1999a; Roberts et al. 2001). The early death is caused by enhanced LIF signalling, since 
SOCS3-/- mice showed altered trophoblast differentiation. Animals, in which the SOCS3 
deletion in the placenta was rescued by a tetraploid rescue method, showed extended 
embryonic life. However, rescued SOCS3-/- embryos died due to cardiac hypertrophy 
(Takahashi et al. 2003). 
4.1 SOCS3 in myeloid cells/granulopoiesis  
Mice with a conditional knock down of SOCS3 in myeloid cells demonstrated the role of 
SOCS3 in suppression of IL-6/gp130 signalling. SOCS3-deficient macrophages stimulated 
with IL-6 displayed an increased magnitude and duration of STAT1 and STAT3 activation 
in comparison to controls (Croker et al. 2003; Lang et al. 2003; Yasukawa et al. 2003a).  
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Mice deficient for SOCS3 in myeloid cells are resistant to LPS-induced endotoxic shock 
whereas STAT3 deficient mice are highly sensitive (Takeda et al. 1999; Yasukawa et al. 
2003a). Thus, STAT3 activation mediates anti-inflammatory IL-10 signalling and in the 
absence of SOCS3, similar anti-inflammatory properties in response to IL-6 (Johnston & 
O'Shea 2003). Furthermore, macrophages lacking SOCS3 were shown to secrete reduced 
levels of TNF- and IL-12 after IL-6 and LPS stimulation (Yasukawa et al. 2003a).   
In a similar manner, DCs deficient for STAT3 contributed to T cell hyper-activation while in 
the absence of SOCS3, DCs induced a selective expansion of regulatory T cells (Cheng et al. 
2003; Matsumura et al. 2007). An overexpression of SOCS3 in DCs resulted a reduction of 
expression of co-stimulatory molecules and IL-12. Moreover, SOCS3-deficient and 
overexpressing DCs had the capacity to suppress EAE development (Li et al. 2006; 
Matsumura et al. 2007). 
Croker et al. (2003) and Lang et al (2003) on the other hand, using SOCS3 deficient 
macrophages found an increased STAT1 activation and elevated levels of IFN--regulated 
genes in response to IL-6. 
 
 
Fig. 4. SOCS3 inhibits anti-inflammatory and IFN-inducible genes in response to IL-6. 
Adapted from (Johnston & O'Shea 2003) 
Other molecular targets of SOCS3 have been reported: SOCS3 inhibited the activation of 
TNF-receptor-associated factor 6 (TRAF6) and TGF--activated kinase 1 (TAK1), essential 
for both TLR– and IL-1-induced responses (Frobose et al. 2006). Prele et al. (2006) found no 
differences in LPS responses of SOCS3 transfected human macrophages. Thus, further 
studies are required to determine whether there is a direct role for SOCS3 in TLR 
signalling. 
Upon over-expression, SOCS3 was found to bind to the GCSF receptor and reduced STAT3 
activation in response to GCSF (Hortner et al. 2002b; Hermans et al. 2003). In agreement, 
deletion of SOCS3 in the myeloid or hematopoietic cells increased numbers of neutrophils, 
which showed increased survival and proliferative capacity (Croker et al. 2004; Kimura et al. 
2004). Following GCSF injection SOCS3-deficient mice developed neutrophilia, and a 
spectrum of inflammatory pathologies, characterised by neutrophil infiltration in multiples 
tissues (Croker et al. 2008). Overall, SOCS3 regulates survival, growth and activation of 
neutrophils and an inhibition of SOCS3 may enhance the essential neutrophil recovery after 
chemotherapy or neutropenia.  
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4.1.1 SOCS3 in T cells 
T cell development in the thymus is unaffected by SOCS3 (Chen et al. 2006). However, 
SOCS3 might play an active role in T cell proliferation and differentiation.  
The proliferation of T cells was found to be regulated by SOCS3. T cells overexpressing 
SOCS3 showed reduced proliferation to mitogens and anti-CD28 (Banerjee et al. 2002; 
Matsumoto et al. 2003). On the other hand, SOCS3-deficient CD8 T cells also showed 
enhanced anti-CD3-induced proliferation. Neutralization of IL-27 also limited T cell 
proliferation indicating that IL-27 responses are impaired by SOCS3 and account for 
diminished  T cell proliferation (Brender et al. 2007). 
There is a reciprocal relation between SOCS1 and SOCS3 expression levels in T cells, with 
high SOCS1 and low SOCS3 expression in Th1 cells whereas high SOCS3 and low SOCS1 
expression was found in Th2 cells (Egwuagu et al. 2002; Seki et al. 2003).  However, there are 
conflicting results whether levels of SOCS3 actively influences the Th1/Th2 balance. 
Overexpression of SOCS3 in murine T cells resulted in elevated Th2 and decreased Th1 
responses during allergy. Furthermore, a reduced Th2 response characterized by decreased 
IL-4 and increased IFN- production was shown in SOCS3+/- mice (Seki et al. 2003). A SOCS3 
mediated regulation of STAT5 activation was reported to account for the altered Th1/Th2 
balance. Another explanation for reduced Th2 responses was suggested by Kinjyo et al. 
(2006) using Lck SOCS3fl/fl mice, in which Th3-like T cells with higher IL-10 and TGF- 
levels were found. These cytokines may then suppress Th1 responses accounting for the 
decreased Th1/Th2 ratio in SOCS3 deficient mice. However this observation was not 
confirmed by others: mice with a specific deletion of SOCS3 in the lymphoid cells were 
reported to have an unaltered Th1 and Th2 cell differentiation (Chen et al. 2006). Instead, 
loss of SOCS3 resulted in enhanced Th17 generation and enhanced STAT3 activation in 
response to IL-23. Th17 is a T cell subset that produces IL-17 and  plays a key role in 
different autoimmune diseases and in the defense against fungal infections. STAT3 
interacted with the IL17A and IL-17F promoter (Kinjyo et al. 2006). TGF--mediated the 
inhibition of SOCS3 expression and therefore prolonged STAT3 activation promoting Th17 
development (Qin et al. 2009).  
The importance of SOCS3 in impairing Th17 development was further confirmed in a study 
of an atherosclerosis model in mice with a T cell specific SOCS3 knock down and in a 
rheumatoid arthritis model in mice lacking SOCS3 in hematopoietic and endothelial cells 
(Wong et al. 2006; Taleb et al. 2009).  
 
 
Fig. 5. SOCS3 hampers Th17 cell development 
Regulatory T cells, a subset of CD4 T cells that suppress T cell-mediated immune responses 
and maintain tolerance to self-antigens, were found to be deficient for SOCS3 protein 
expression (Pillemer et al. 2007). Over-expression of SOCS3 in T regs impaired their 
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proliferation and suppressive function. The role of SOCS3 on T cell differentiation is still not 
completely understood but it seems likely that SOCS3 impedes both T reg function (and 
thereby increasing immune responses) and Th17 differentiation (impairing inflammatory 
responses, fig. 5).  
SOCS3 has also been shown to modulate B cell development by affecting the lodging of 
precursor B cells to the bone marrow, via the regulation of responses to CXCL12 (Le et al. 
2007). 
4.1.2 SOCS3 in leptin and insulin resistance 
Infections are accompanied by tissue insulin resistance, as manifested by worsening of 
metabolic control in diabetic patients and decreased glucose tolerance in non-diabetic 
subjects. A propensity towards glucose intolerance and diabetes has been documented in 
patients with chronic HCV infection. Diabetes patients are more susceptible to infections 
such as tuberculosis or candidiasis. These associated diseases could be linked to SOCS 
expressin. As stated below pathogen molecules can stimulate SOCS3 expression. SOCS3 
binds to the leptin and insulin receptor and inhibits STAT3 activation in response to leptin 
and insulin respectively (Clement et al. 1998; Bjorbak et al. 2000; Emanuelli et al. 2000; 
Eyckerman et al. 2000; Chen et al. 2006). Leptin is an adipocyte-derived hormone that 
regulates food intake and energy homeostasis (Flier 2004). Leptin-resistance, common in 
human obesity and in acquired obesity in rodents, may be regulated by SOCS3 (Bjorbaek 
et al. 1998). High fat diet fed SOCS3+/- mice as well as neural cell-specific SOCS3- knock-
down mice showed reduced diet-induced obesity, together with increased leptin and 
insulin sensitivity (Howard et al. 2004; Mori et al. 2004; Kievit et al. 2006). Furthermore, 
SOCS3 deficient adipocytes were protected from TNF--induced insulin resistance (Shi et 
al. 2004). However, mice with a knock down of SOCS3 in hepatocytes displayed increased 
insulin sensitivity in the liver but developed obesity and systemic insulin resistance with 
age (Torisu et al. 2007). This insulin resistance was accounted by increased inflammatory 
responses due to the lack of SOCS3. Accordingly, overexpression of SOCS3 in the liver of 
mice induced insulin resistance, whereas silencing of SOCS3 with antisense 
oligonucleotides in obese diabetic mice improved insulin sensitivity (Ueki et al. 2004a; 
Ueki et al. 2004b). The consistency of the effect of SOCS3 in different approaches on both 
leptin and insulin resistance indicates SOCS3 as a unique mediator of both obesity and 
insulin resistance. 
4.2 Role of SOCS3 in infectious diseases and inflammation 
Similar to SOCS1, SOCS3 expression can be stimulated by both cytokines but also TLR 
agonists. Additionally, several pathogens including viruses, bacteria and parasites have 
been shown to stimulate SOCS3 expression. But due to multiple binding partners of SOCS3, 
it is hard to predict the role of  SOCS3 in different infections.   
4.2.1 Viral infections 
SOCS3 was found to inhibit type I IFN signalling although SOCS3 was less effective than 
SOCS1 (Song & Shuai 1998; Shen et al. 2000). Infection with several viruses induced SOCS3 
expression that correlated with reduced STAT1 activation in response to IFN-. HSV 
stimulated SOCS3 in different human cell lines but not in the B-cell line AKATA. In contrast 
to SOCS3-expressing cell lines, infected AKATA cells showed no impaired IFN- 
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mediated STAT1 activation during HSV infection. Silencing of SOCS3 using anti-sense 
nucleotides significantly hampered replication of HSV (Yokota et al. 2005). Similar 
observations were done during Influenza A, HCV and Epstein Barr virus infections 
indicating that SOCS3 expression facilitates viral infections (Bode et al. 2003; Le Goffic et al. 
2007; Pothlichet et al. 2008; Michaud et al. 2010). 
Interestingly, mice with a T cell-specific SOCS3 deletion showed increased T cell activation 
and viral clearance without development of immunopathology during the infection with 
lymphocytic chriomeningitis virus (LCMV) (Pellegrini et al. 2011). Treatment of LCMV- 
infected mice with IL-7 repressed SOCS3 expression and promoted IL-6 production 
resulting in enhanced T cell effector functions, numbers and viral clearance. However, the 
deletion of SOCS3 in all hematopoietic cells induced neutrophilia and early lethality in 
LCMV-infected mice (Pellegrini et al. 2011).  
Patients with genotype 1 HCV infection tend to have higher levels of SOCS3 expression, 
providing a rationale for their propensity toward a lack of therapeutic response (Kim et al. 
2009). Moreover, one SOCS3 genotype (–4874 AA) expressed SOCS3 at elevated levels and 
showed a poorer response to therapy (Persico et al. 2008). 
4.2.2 Bacterial infections 
The infection of macrophages with Salmonella enterica has been shown to increment SOCS3 
but not SOCS1 expression (Uchiya & Nikai 2005). SOCS3 stimulation was dependent on the 
Salmonella pathogenicity island 2 important for bacterial virulence. Infected macrophages 
showed impaired STAT1 and STAT3 activation in response to IL-6 or IFN- respectively, 
which might prevent effective bacterial killing. 
Infection of macrophages with Mycobacterium avium or M. bovis raised SOCS1 and SOCS3 
levels in a TLR2-NOTCH1 dependent pathway (Imai et al. 2003; Vazquez et al. 2006; 
Narayana & Balaji 2008). 
Patients with active tuberculosis were found to have higher SOCS3 expression levels in 
whole blood and T cells in comparison to latently infected controls or to patients after 
chemotherapy (Mistry et al. 2007; Jacobsen et al. 2010). We observed that SOCS3 expression 
in blood non-T cells from patients with TB was negatively associated with severity of 
disease (Masood et al, 2011). Atogether the role of SOCS3 in bacterial infections is far from 
clear. 
4.2.3 Parasites 
Little is known about the role of SOCS3 in parasites. Infection of macrophages with the 
parasite Leishmania dovani was shown to stimulate SOCS3 expression. SOCS3 levels 
associated with reduced STAT1 activation after IFN- stimulation and therefore with 
reduced protection (Bertholet et al. 2003).   
On the contrary, mice lacking SOCS3 in T cells were more susceptible to Leishmania major 
infections. SOCS3-deficiency in T cells led to increased anti-inflammatory TGF- and IL-10 
secretion by T cells and reduced immunoglobulin levels (Kinjyo et al. 2006).   
Mice bearing a mutation in the SOCS3 binding site of the gp130 receptor displayed 
increased susceptibility to Toxoplasma gondii. A decreased IL-12 production by DCs resulted 
in reduced IFN- secretion by NK cells of these mice. Addition of IL-12 as well as 
neutralization of IL-6 could restore the wild type phenotype indicating that an altered IL-6 
signalling was responsible for increased susceptibility (Silver et al. 2011). 
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S 
O 
C 
S 
1 
pathogen mechanism pathology 
pathogen 
control 
SFV   IFN- signalling   worsened 
HTLV-1   IFN- signalling.  worsened 
VSV   IFN- signalling.  worsened 
HSV-1   IFN- signalling.  worsened 
Vaccinia Virus  immune responses improved improved 
HIV-1 Ubiquitination of HIVgag  worsened 
C. pneumoniae IFN- signalling  improved worsened 
M. tuberculosis – M. bovis BCG  IL-12 signalling  improved worsened 
P. berghi ANKA   ??? worsened worsened 
L. major   IFN- signalling  improved worsened 
T. gondii   IFN- signalling   worsened 
B. malayi  Th1/Th2 ratio  worsened 
S 
O 
C 
S 
3 
HSV-1  IFN-  signalling.  worsened 
RSV IFN-  signalling.   
HIV-1 IFN-  signalling   
Influenza A Virus  IFN- signalling   worsened 
LCMV  T cell activation worsened worsened 
L. major  TGF- IL-10 production 
by T cells 
? improved 
T. gondii (gp130 mutation) IL-12 induction in 
dendritic cells 
improved improved 
Table 1. Role of SOCS molecules during microbial infections. 
5. Conclusion 
SOCS expression is tightly regulated to prevent inflammation while maintaining protective 
anti-microbial responses. Pathogens are able to potently stimulate SOCS1 and 3 protein 
expression following infection and hijack SOCS function promoting their survival. In most 
infections studied, the stimulation of SOCS1 and SOCS3 expression by infectious agents 
resulted in a worsened pathogen control even though the nature of immune inhibition by 
the SOCS proteins differed. Thus, SOCS proteins can be manipulated to increase innate 
immune mechanisms, but also the triggering and the magnitude of adaptive immune 
responses. This converts SOCS proteins into very attractive therapeutic targets. However 
manipulation of SOCS levels always bears the risk of increased inflammatory responses. A 
better understanding of the role of SOCS in infections is required to better gauge SOCS 
manipulation leading to potentially new therapies. 
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